Plasminogen activator inhibitor in human tears after laser refractive surgery. 2008

Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
Department of Ophthalmology, University of Debrecen, Medical and Health Science Center, Faculty of Medicine, Debrecen, Hungary.

OBJECTIVE To observe levels of plasminogen activator inhibitor (PAI) in human tears after photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). METHODS University medical center eye clinic. METHODS Tear samples were collected from 46 eyes having PRK and 13 eyes having LASIK immediately before and after surgery and on the first (LASIK), third (PRK), and fifth (PRK) postoperative days. Analyses used enzyme-linked immunoassay, yielding 61 PRK PAI-1 determinations and 146 PRK and 35 LASIK PAI-2 determinations. RESULTS All determinations of PRK PAI-1 were below the detection limit of 1 ng/mL of the original tear sample. In the PRK eyes, the mean PAI-2 concentration was 19.8 ng/mL +/- 23.4 (SD) in preoperative tears, 112.7 +/- 60.5 ng/mL immediately postoperatively, 12.1 +/- 19.5 ng/mL after 3 days, and 15.5 +/- 20.4 ng/mL after 5 days. In the LASIK eyes, the mean PAI-2 concentration was 19.0 +/- 33.1 ng/mL preoperatively, 111.5 +/- 69.2 ng/mL immediately postoperatively, and 15.7 +/- 18.8 ng/mL after 1 day. CONCLUSIONS The similarity in the general time pattern of PAI-2 after PRK and LASIK suggests commonality in the enzymatic control response to corneal surgical wounding. Taken in the context of previous work, the observed levels of PAI-2 concentration in eyes with and without opacification suggest that in the postsurgical period, PAI-2 is not the controlling mechanism for the later development of corneal opacification and haze.

UI MeSH Term Description Entries
D009216 Myopia A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness. Nearsightedness,Myopias,Nearsightednesses
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005136 Eye Proteins PROTEINS derived from TISSUES of the EYE. Proteins, Eye
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013666 Tears The fluid secreted by the lacrimal glands. This fluid moistens the CONJUNCTIVA and CORNEA. Meibomian Lipids,Meibum,Lipid, Meibomian,Meibomian Lipid,Tear
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D017395 Plasminogen Activator Inhibitor 1 A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. PAI-1,SERPINE1 Protein,Serpin E1,Type 1 Plasminogen Activator Inhibitor,E1, Serpin,Protein, SERPINE1
D017396 Plasminogen Activator Inhibitor 2 Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. PAI-2,Serpin B2,Type 2 Plasminogen Activator Inhibitor

Related Publications

Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
January 1992, Eye (London, England),
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
August 1991, Acta ophthalmologica,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
July 1990, Experimental eye research,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
June 1989, The Journal of clinical endocrinology and metabolism,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
October 2014, Journal of thrombosis and haemostasis : JTH,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
February 2000, Yonsei medical journal,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
December 1992, Arthritis and rheumatism,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
February 1988, Experimental eye research,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
January 2006, Klinika oczna,
Adrienne Csutak, and David M Silver, and József Tozsér, and Zita Steiber, and Peter Bagossi, and Ziad Hassan, and András Berta
November 1984, Biochimica et biophysica acta,
Copied contents to your clipboard!